Publications by authors named "P Baudoin"
Article Synopsis
- The study aimed to evaluate if a combination of patient-reported outcomes related to health, disability, pain, quality of life, and fatigue could help detect active disease in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients.
- Researchers analyzed data from 683 RA patients and 525 PsA patients, measuring the correlation between changes in these outcomes and clinically defined active disease.
- Results showed that declines in general health, disability, quality of life, and pain were significantly linked to active disease, indicating that this combination of measures could effectively serve as a screening tool for monitoring these conditions remotely.
Objective: Persistent articular inflammation in psoriatic arthritis (PsA) is associated with radiographic damage. Despite advances in diagnosis and therapy, radiographic structural damage remains prevalent in PsA. To elucidate this topic, we studied which baseline clinical characteristics determine radiographic progression.
View Article and Find Full Text PDFArticle Synopsis
- - The study evaluated long-term outcomes for patients with rheumatoid arthritis (RA) or undifferentiated arthritis (UA) after 12 and 20 years of treatment in two trials: BeSt and IMPROVED, focusing on achieving low disease activity or remission.
- - In the long-term follow-up, 91% of ex-BeSt and 68% of ex-IMPROVED patients achieved low disease activity or remission, with mild progression of radiographic damage and limited functional disability reported.
- - Overall, most patients remained in remission and experienced little functional impairment two decades after initial treatment, indicating the effectiveness of the targeted treatment approach over the long term.
Objectives: To investigate whether there is a window of opportunity for psoriatic arthritis (PsA) patients and to assess which patient characteristics are associated with a longer diagnostic delay.
Methods: All newly diagnosed, disease-modifying antirheumatic drug-naïve PsA patients who participated in the Dutch southwest Early PsA cohoRt and had ≥3 years of follow-up were studied. First, total delay was calculated as the time period between symptom onset and PsA diagnosis made by a rheumatologist and then split into patient and physician delays.
Objective: The randomised placebo-controlled GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) trial evaluated the benefits and harms of prednisolone 5 mg/day added to standard care for 2 years in patients aged 65+ years with rheumatoid arthritis (RA). Here, we studied disease activity, flares and possible adrenal insufficiency after blinded withdrawal of study medication.
Methods: Per protocol, patients successfully completing the 2-year trial period linearly tapered and stopped blinded study medication in 3 months.